Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessment of Talquetamab in Treating Relapsed/Refractory Multiple Myeloma: Insights from an International Immunotherapy Registry Analysis

  • By

  • Murali Janakiram

  • Carlyn R. Tan

  • Hira Mian

  • Chiung-Yu Huang

  • Rakesh Popat

  • Joaquín Martínez-Lopez

  • Efsthathios Kastritis

  • Wee-Joo Chng

  • Prashant Kapoor

  • Mrugakshi Dave

  • Susan Bal

  • Laurent Garderet

  • Andre De Menezes Silva Corraes

  • Christine Riedhammer

  • Torsten Steinbrunn

  • Magdalene Corona

  • Chandramouli Nagarajan

  • Hermann Einsele

  • Tom Martin

  • Amrita Krishnan

  • Yi Lin

  • May 19, 2026

Share

Objective:

To characterize real-world patterns of talquetamab use, evaluate safety and tolerability, and assess real-world outcomes including response rates, progression-free survival (PFS), and overall survival (OS) in patients with relapsed refractory multiple myeloma (RRMM).

Approach:
  • Study Design: International multicenter retrospective study involving nine academic centers across five countries, focusing on patients treated with talquetamab.
  • Patient Inclusion: Patients who received at least one cycle of talquetamab were included; those receiving it as bridging for CART therapy were excluded from survival analyses.
  • Data Collection: Data on patient characteristics, treatment details, and adverse events (AEs) were collected and analyzed using IMWG response criteria.
Key Findings:
  • A total of 151 patients were included, with a median age of 64 years; 91% were triple-refractory and 53% were penta-refractory.
  • Cytokine release syndrome (CRS) occurred in 26% of patients after the first step-up dose, primarily low grade.
  • Skin and nail toxicities were reported in 40% of patients, with skin dryness being the most common manifestation.
Interpretation:

Real-world data indicate that talquetamab is associated with manageable safety profiles and response rates in a heavily pretreated RRMM population.

Limitations:
  • The study's retrospective nature may introduce biases.
  • Strict eligibility criteria in clinical trials may limit generalizability of findings.
Conclusion:

Talquetamab demonstrates a favorable safety profile and efficacy in real-world settings for patients with RRMM.

Original Source(s)

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis

  • by Murali Janakiram, Carlyn R. Tan, Hira Mian, Chiung-Yu Huang, Rakesh Popat, Joaquín Martínez-Lopez, Efsthathios Kastritis, Wee-Joo Chng, Prashant Kapoor, Mrugakshi Dave, Susan Bal, Laurent Garderet, Andre De Menezes Silva Corraes, Christine Riedhammer, Torsten Steinbrunn, Magdalene Corona, Chandramouli Nagarajan, Hermann Einsele, Tom Martin, Amrita Krishnan, Yi Lin

  • May 19, 2026

Related Content

Large-cohort screening projects in seven regions of China demonstrate the efficacy of extended HPV genotyping in triaging HPV-positive women

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors